{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:07:55Z","timestamp":1791122875403,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejmech.2025.117643","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:27:42Z","timestamp":1744878462000},"page":"117643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["New drugs approved by the NMPA in 2024: Synthesis and clinical applications"],"prefix":"10.1016","volume":"291","author":[{"given":"Xinxin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117643_bib1","article-title":"Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117643_bib2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40265-024-02072-x","article-title":"Tunlametinib: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114008","article-title":"A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-Mutant melanoma","volume":"202","author":"Wei","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117643_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1039416","article-title":"Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117643_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40164-024-00528-0","article-title":"Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study","volume":"13","author":"Shi","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib6","series-title":"Benzoheterocyclic Compounds and Use Thereof","author":"Tian","year":"2014"},{"key":"10.1016\/j.ejmech.2025.117643_bib7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543784.2017.1353077","article-title":"Entinostat for the treatment of breast cancer","volume":"26","author":"Trapani","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib8","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/ijms20071616","article-title":"Mechanism of action for HDAC inhibitors-insights from omics approaches","volume":"20","author":"Li","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117643_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13395-019-0198-x","article-title":"Preclinical rationale for entinostat in embryonal rhabdomyosarcoma","volume":"9","author":"Bharathy","year":"2019","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.ejmech.2025.117643_bib10","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","article-title":"Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117643_bib11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Roussos Torres","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejmech.2025.117643_bib12","series-title":"Preparation of Benzamide Derivatives as Anticancer Agents","author":"Suzuki","year":"1998"},{"key":"10.1016\/j.ejmech.2025.117643_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-023-01454-z","article-title":"Efficacy, safety and pharmacokinetics of unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a phase I\/II trial","volume":"8","author":"Lu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejmech.2025.117643_bib14","series-title":"Preparation of Pyridine Compounds as Inhibitors of c-Met And\/Or ALK Kinases","author":"Zhang","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117643_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40265-023-01990-6","article-title":"Repotrectinib: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib16","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1097\/MS9.0000000000002717","article-title":"Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer","volume":"86","author":"Rais","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.ejmech.2025.117643_bib17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117643_bib18","series-title":"Drugs and Lactation Database (Lactmed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117643_bib19","article-title":"Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China","volume":"14","author":"Zhong","year":"2024","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ejmech.2025.117643_bib20","series-title":"Preparation of Fluorodimethyltetrahydroethenopyrazolobenzoxatriazacyclotridecinone Derivatives for Use as Antitumor Agents","author":"Cui","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117643_bib21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jtho.2022.01.015","article-title":"Safety, efficacy, and pharmacokinetics of rezivertinib (BPI-7711) in patients with advanced NSCLC with EGFR T790M mutation: a phase 1 dose-escalation and dose-expansion study","volume":"17","author":"Shi","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","article-title":"Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib23","series-title":"Preparation of Substituted 2-anilinopyrimidine Derivatives as EGFR Modulators","author":"Peng","year":"2016"},{"key":"10.1016\/j.ejmech.2025.117643_bib24","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.21037\/tlcr-24-604","article-title":"Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-na\u00efve advanced ALK-Positive non-small cell lung cancer: a systematic review and network meta-analysis","volume":"13","author":"Li","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117643_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41392-023-01538-w","article-title":"Envonalkib versus crizotinib for treatment-naive ALK-Positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejmech.2025.117643_bib26","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S1470-2045(13)70169-4","article-title":"Inhibition of HSP90 molecular chaperones: moving into the clinic","volume":"14","author":"Garcia-Carbonero","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib27","series-title":"Process for Preparation of Pyridine Substituted 2-aminopyridine Protein Kinase Inhibitor Crystal","author":"Gong","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117643_bib28","doi-asserted-by":"crossref","first-page":"S1119","DOI":"10.1016\/j.jtho.2021.08.540","article-title":"P51.03 oritinib (SH-1028), a third-generation EGFR-TKI in advanced NSCLC patients with positive EGFR T790M: results of a single-arm phase Ib trial","volume":"16","author":"Zhou","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib29","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.annonc.2022.02.016","article-title":"7MO oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: results of a single-arm phase II trial","volume":"33","author":"Zhou","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib30","series-title":"Method for Preparing Tricyclic Compound as EGFR Kinase Inhibitor","author":"Zhao","year":"2019"},{"key":"10.1016\/j.ejmech.2025.117643_bib31","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40265-024-02089-2","article-title":"Golidocitinib: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib32","article-title":"Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.117643_bib33","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cncr.35272","article-title":"Golidocitinib favorable for relapsed\/refractory T-cell lymphoma","volume":"130","author":"Nierengarten","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2025.117643_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib35","series-title":"Preparation of Substituted 2-(piperazin-1-yl)-N-[3-[2-[(1H-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl] Propanamide as Selective JAK1 Inhibitors for Treating Cancers and Immune Disorders","author":"Aastrand","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117643_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40265-025-02148-2","article-title":"Correction: fulzerasib: first approval","volume":"85","author":"Lamb","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib37","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-024-02120-6","article-title":"Fulzerasib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib38","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jtho.2024.08.005","article-title":"Efficacy and safety of KRASG12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study","volume":"19","author":"Zhou","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib39","series-title":"Preparation of Heteroaromatic Ring Dihydropyrimidinone Derivatives as KRAS Gene Mutation Inhibitors Useful in the Treatment of Cancer","author":"Zhou","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117643_bib40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/14737140.2023.2282606","article-title":"Efficacy and toxicity of drugs targeting KRAS(G12C) mutation in non-small cell lung cancer: a meta-analysis","volume":"23","author":"Luo","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2025.117643_bib41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2025.117643_bib42","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","article-title":"D-1553 (garsorasib), a potent and selective inhibitor of KRAS(G12C) in patients with NSCLC: phase 1 study results","volume":"18","author":"Li","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib43","series-title":"Heterocyclic Compounds, Preparation Methods and Uses Thereof in the Treatment of Cancers","author":"Dai","year":"2020"},{"key":"10.1016\/j.ejmech.2025.117643_bib44","article-title":"The climb toward intracranial efficacy: Zorifertinib in EGFR-mutant NSCLC with CNS metastases in the EVEREST trial","volume":"6","author":"Roy-O'Reilly","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2025.117643_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.09.002","article-title":"First-line zorifertinib for EGFR-Mutant non-small cell lung cancer with central nervous system metastases: the phase 3 EVEREST trial","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2025.117643_bib46","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117643_bib47","doi-asserted-by":"crossref","first-page":"S788","DOI":"10.1016\/j.annonc.2023.09.2406","article-title":"1373P efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC): interim analysis of global TRUST-II study","volume":"34","author":"P\u00e9rol","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2021.09.005","article-title":"NTRK fusions in lung cancer: from biology to therapy","volume":"161","author":"Harada","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.117643_bib49","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.24.00731","article-title":"Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: the phase II TRUST-I study","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13543784.2024.2305131","article-title":"Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data","volume":"33","author":"Nagasaka","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib51","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1200\/JCO.24.01062","article-title":"Taletrectinib: TRUST in the continued evolution of treatments for ROS1 fusion-positive lung cancer","volume":"42","author":"Waliany","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2022-1059","article-title":"TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors","volume":"19","author":"Nagasaka","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2025.117643_bib53","series-title":"Preparation of imidazo[1,2-b]pyridazine Derivatives as Potent Inhibitors of ROS1 Kinase and NTRK Kinase","author":"Takeda","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117643_bib54","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/dom.14926","article-title":"Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Gao","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejmech.2025.117643_bib55","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/dom.14971","article-title":"Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Ji","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejmech.2025.117643_bib56","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40262-022-01209-z","article-title":"A model-informed approach to accelerate the clinical development of janagliflozin, an innovative SGLT2 inhibitor","volume":"62","author":"Song","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.117643_bib57","series-title":"Drugs and Lactation Database (Lactmed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117643_bib58","series-title":"Optically Pure benzyl-4-chlorophenyl-C-glucoside Derivatives as SGLT Inhibitors (Diabetes Mellitus)","author":"Wu","year":"2015"},{"key":"10.1016\/j.ejmech.2025.117643_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/dom.16014","article-title":"Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"27","author":"Gao","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejmech.2025.117643_bib60","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/dom.15348","article-title":"A model-informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong-acting dipeptidyl peptidase-4 inhibitor","volume":"26","author":"Cui","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejmech.2025.117643_bib61","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1111\/dom.15915","article-title":"Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: a randomized, double-blind, non-inferiority trial","volume":"26","author":"Ren","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejmech.2025.117643_bib62","series-title":"Amino Pyranoid Ring Derivative as DPP-IV Inhibitor and Its Preparation","author":"Zhang","year":"2015"},{"key":"10.1016\/j.ejmech.2025.117643_bib63","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cpdd.895","article-title":"Safety, pharmacokinetics, and pharmacodynamics of a dipeptidyl Peptidase-4 inhibitor: a randomized, double-blinded, placebo-controlled daily administration of fotagliptin benzoate for 14 days for type 2 diabetes mellitus","volume":"10","author":"Wu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ejmech.2025.117643_bib64","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12916-023-03089-x","article-title":"Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Xu","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.ejmech.2025.117643_bib65","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17425255.2021.1915283","article-title":"Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects","volume":"17","author":"Ding","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejmech.2025.117643_bib66","series-title":"Preparation of 3-(3-aminopiperidine-1-yl)-5-oxo-1,2,4-triazine Benzoate and Pharmaceutical Composition Thereof","author":"Tan","year":"2015"},{"key":"10.1016\/j.ejmech.2025.117643_bib67","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40262-024-01427-7","article-title":"Use of a PK\/PD model to select Cetagliptin dosages for patients with type 2 diabetes in phase 3 trials","volume":"63","author":"Lu","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.117643_bib68","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/dom.15601","article-title":"Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"26","author":"Guo","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejmech.2025.117643_bib69","first-page":"74","article-title":"[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction]","volume":"49","author":"Hu","year":"2018","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.ejmech.2025.117643_bib70","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/14728214.2016.1257608","article-title":"An update on DPP-4 inhibitors in the management of type 2 diabetes","volume":"21","author":"Cahn","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","article-title":"2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Kim","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117643_bib72","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40265-024-02079-4","article-title":"Correction: tegileridine: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib73","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40265-024-02033-4","article-title":"Tegileridine: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib74","series-title":"Oxa Spiro Derivative Useful in Treatment of Pain and pain-related Disease and Its Preparation","author":"Li","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117643_bib75","series-title":"Drugs and Lactation Database (Lactmed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117643_bib76","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","article-title":"Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study","volume":"6","author":"Jang","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmech.2025.117643_bib77","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/bloodadvances.2024014652","article-title":"Patient-reported improvements in patients with PNH treated with iptacopan from two phase 3 studies","volume":"9","author":"Risitano","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmech.2025.117643_bib78","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1080\/14656566.2024.2404110","article-title":"Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"de Castro","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejmech.2025.117643_bib79","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1021\/acs.jmedchem.9b01870","article-title":"Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (LNP023), a factor B inhibitor specifically designed to be applicable to treating a diverse array of complement mediated diseases","volume":"63","author":"Mainolfi","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117643_bib80","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.3390\/ijms24065446","article-title":"Eptifibatide, an older therapeutic peptide with new indications: from clinical pharmacology to everyday clinical practice","volume":"24","author":"Tonin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117643_bib81","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1080\/03007995.2024.2423740","article-title":"Treatment of cerebral venous thrombosis: a review","volume":"40","author":"Patel","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejmech.2025.117643_bib82","series-title":"Synthesis of N2-(3-mercapto-1-oxopropyl)-L-arginylglycyl-L-\u03b1-aspartyl-L-\u03b1-tryptophyl-L-\u03b1-prolyl-L-\u03b1-cysteinamide Cyclic (1\u21926)-disulfide and Its Analogues","author":"Tan","year":"2007"},{"key":"10.1016\/j.ejmech.2025.117643_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.709974","article-title":"Durlobactam, a new diazabicyclooctane \u03b2-Lactamase inhibitor for the treatment of acinetobacter infections in combination with sulbactam","volume":"12","author":"Shapiro","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2025.117643_bib84","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.3390\/jcm11123258","article-title":"Durlobactam in the treatment of multidrug-resistant Acinetobacter baumannii infections: a systematic review","volume":"11","author":"Granata","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.117643_bib85","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1093\/cid\/ciad095","article-title":"Durlobactam, a broad-spectrum serine \u03b2-lactamase inhibitor, restores sulbactam activity against acinetobacter species","volume":"76","author":"Papp-Wallace","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117643_bib86","series-title":"Drugs and Lactation Database (Lactmed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2025.117643_bib87","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/durlobactam: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117643_bib88","first-page":"1","article-title":"Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii","volume":"23","author":"Fu","year":"2024","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ejmech.2025.117643_bib89","series-title":"Preparation of Oxodiazabicyclooctenyl Hydrogen Sulfate Derivatives for Use as beta-lactamase Inhibitors","author":"McGuire","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117643_bib90","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/cid\/ciab763","article-title":"Pradefovir treatment in patients with chronic hepatitis B: week 24 results from a multicenter, double-blind, randomized, noninferiority, phase 2 trial","volume":"74","author":"Gao","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117643_bib91","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12072-017-9797-y","article-title":"Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects","volume":"11","author":"Ding","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ejmech.2025.117643_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104693","article-title":"Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection","volume":"174","author":"Zhang","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ejmech.2025.117643_bib93","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/jm7012216","article-title":"Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B","volume":"51","author":"Reddy","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117643_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116012","article-title":"Absorption, distribution, metabolism and excretion of linaprazan glurate in rats","volume":"242","author":"Zhang","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2025.117643_bib95","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium-competitive acid blockers: current clinical use and future developments","volume":"26","author":"Scarpignato","year":"2024","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.ejmech.2025.117643_bib96","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/jps.23573","article-title":"Solid-state amorphization of linaprazan by mechanical milling and evidence of polymorphism","volume":"102","author":"Willart","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejmech.2025.117643_bib97","series-title":"Process for Preparing a Substituted Imidazopyridine Compound","author":"Elman","year":"2002"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:48:43Z","timestamp":1778042923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":97,"alternative-id":["S0223523425004088"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117643","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drugs approved by the NMPA in 2024: Synthesis and clinical applications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117643"}}